BiotechTube

REGN2477+REGN1033 + Matching placebo

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sporadic Inclusion Body Myositis

Conditions

Sporadic Inclusion Body Myositis

Trial Timeline

Feb 19, 2019 → Nov 5, 2020

NCT ID
NCT03710941

About REGN2477+REGN1033 + Matching placebo

REGN2477+REGN1033 + Matching placebo is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Sporadic Inclusion Body Myositis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03710941. Target conditions include Sporadic Inclusion Body Myositis.

What happened to similar drugs?

0 of 1 similar drugs in Sporadic Inclusion Body Myositis were approved

Approved (0) Terminated (0) Active (1)
🔄Bimagrumab + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03710941Phase 2Withdrawn

Competing Products

7 competing products in Sporadic Inclusion Body Myositis

See all competitors
ProductCompanyStageHype Score
Bimagrumab + PlaceboNovartisPhase 3
40
BYM338 (Bimagrumab)NovartisPhase 2/3
38
BYM338/bimagrumab + PlaceboNovartisPhase 2/3
38
EverolimusNovartisPhase 2
27
BYM338 + PlaceboNovartisPhase 2
35
LDE225 0.75% + VehicleNovartisPhase 2
27
Vandetanib 300 mgSanofiPre-clinical
26